Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,070 | 0,098 | 29.07. | |
0,080 | 0,087 | 29.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Sa | Hemostemix Inc (2): Hemostemix $517,230 (U.S.) debenture private placement | 2 | Stockwatch | ||
Fr | Hemostemix Inc (2): Hemostemix closes $2.96-million private placement | 1 | Stockwatch | ||
Do | Hemostemix Inc.: Hemostemix Closes $2,969,600 Private Placement | 308 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 24, 2025) - Further to Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") June 26 and July 9th press releases, the Company... ► Artikel lesen | |
Do | Hemostemix Inc (2): Hemostemix closes sale of 15 ACP-01 debentures | 5 | Stockwatch | ||
HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
23.07. | Hemostemix Inc.: Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture | 135 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely... ► Artikel lesen | |
18.07. | Hemostemix Inc (2): Hemostemix closes $3-million oversubscribed placement | 4 | Stockwatch | ||
17.07. | Hemostemix Inc.: Hemostemix Closing $3,000,000 Private Placement | 353 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 17, 2025) - Further to the June 26 and July 9th press releases announcing the Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")... ► Artikel lesen | |
11.07. | Hemostemix Inc (2): Hemostemix 3,911,385-share private placement | 2 | Stockwatch | ||
10.07. | Hemostemix Inc (2): Hemostemix closes $2.7M first tranche of placement | 1 | Stockwatch | ||
09.07. | Hemostemix Inc.: Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share | 224 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 9, 2025) - Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") non brokered private placement of $2,500,000 announced June... ► Artikel lesen | |
04.07. | Hemostemix Inc (2): Hemostemix closes $469,366 private placement | 4 | Stockwatch | ||
04.07. | Hemostemix Inc.: Hemostemix Closes $469,366 Private Placement | 416 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally... ► Artikel lesen | |
03.07. | Hemostemix Inc.: Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial | 424 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to share the Journal of Biomedical Research and Environmental Science published Autologous... ► Artikel lesen | |
02.07. | Hemostemix Inc (2): Hemostemix sees Florida pass stem cell therapy bill | 2 | Stockwatch | ||
02.07. | Hemostemix Inc.: Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments! | 272 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a clinical-stage biotechnology company focused on autologous stem cell therapies for cardiovascular... ► Artikel lesen | |
27.06. | Hemostemix Inc.: Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch | 303 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce... ► Artikel lesen | |
27.06. | Hemostemix Inc (2): Hemostemix chairman Lacey subscribes for $1.5M in units | 5 | Stockwatch | ||
26.06. | Hemostemix Inc.: Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture | 159 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company... ► Artikel lesen | |
17.06. | Hemostemix Inc.: Hemostemix Closes Private Placement of $469,366 | 305 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement... ► Artikel lesen | |
30.05. | Hemostemix Inc (2): Hemostemix 1,634,466-share private placement | 3 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,400 | -0,54 % | Märkte am Morgen: Delivery Hero, Thyssenkrupp, Evotec, Sartorius, Coca-Cola, Block, Nvidia | Der DAX hat zum Auftakt in die neue Handelswoche einen relativ ruhigen Handel erlebt. Zeitweise lag er leicht in der Verlustzone. Letzten Endes schloss er dann aber doch 0,08 Prozent im Plus bei 23.307... ► Artikel lesen | |
QIAGEN | 44,285 | +0,72 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
PAION | 0,017 | -16,16 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
VALNEVA | 3,292 | +0,49 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen | |
EPIGENOMICS | 0,920 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
NOVAVAX | 6,050 | -0,38 % | Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose... ► Artikel lesen | |
STRYKER | 347,10 | +0,09 % | Stryker's Inari Medical launches next-gen thrombectomy system | ||
CRISPR THERAPEUTICS | 51,50 | 0,00 % | The 3 Things That Matter for CRISPR Therapeutics Now | ||
CO.DON | 0,025 | +13,64 % | CO.DON GmbH ist Partner des EU-geförderten Projekts zur Weiterentwicklung des 3D-Bioprinting für die Geweberegeneration | Teltow (ots) - Das im Dezember 2024 gestartete EU-geförderte Projekt micro2MACRO (m2M) zielt darauf ab, die Geweberegeneration durch eine innovative Bioprinting-Plattform voranzutreiben. m2M konzentriert... ► Artikel lesen | |
OCUGEN | 0,905 | +1,09 % | Ocugen, Inc. - 8-K, Current Report | ||
MAINZ BIOMED | 1,820 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und CARE schließen Kooperationsvereinbarung für gemeinsames Versorgungskonzept für Krankenkassen | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und CARE schließen Kooperationsvereinbarung für gemeinsames Versorgungskonzept für Krankenkassen... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 40,140 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 35,950 | +4,02 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,590 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,950 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th |